Ivosidenib, the first IDH1 inhibitor, has shown significant improvements in both PFS (2.7 vs. 1.4 months) and OS (10.3 vs. 5.1 months [adjusted median OS]) compared to placebo in patients with chemorefractory IDH1-mutated CCA [67]. The gene discussed is IDH1; the disease is cholangiocarcinoma.